Daniel S. Lynch has served as chairman of our board of directors since May 2011, when he joined Third Rock Ventures as an entrepreneur-in-residence. Since October 2007, Mr. Lynch has advised and served as executive chair or member of the board of directors for a number of private biopharmaceutical companies, which include Stromedix, Inc. (until its acquisition by Biogen Idec in February 2012), Avila Therapeutics, Inc. (until its acquisition by Celgene Corporation in February 2012), Translate Bio, Inc. (formerly known as RaNA Therapeutics, Inc.), Nimbus Discovery, LLC, Edimer Pharmaceuticals, Ember Therapeutics, Inc., Proclara Biosciences, Inc., and Surface Oncology, Inc. He currently serves on the board of directors of Blueprint Medicines Corporation, and Eleven Biotherapeutics, Inc., and formerly for BIND Biosciences, Inc. Mr. Lynch joined Third Rock Ventures, L.P., or Third Rock, as an entrepreneur-in-residence in May 2011, and became a Venture Partner in May 2013, and now he is a senior advisor. Previously, Mr. Lynch served as chief executive and chief financial officer of ImClone Systems Corporation, or ImClone. As ImClone’s chief executive officer, he led ImClone through a significant turnaround, helping to restore the company’s reputation and to secure FDA approval of ERBITUX (Cetuximab), a novel cancer treatment. As its chief financial officer, Mr. Lynch led negotiations to form the major partnership between ImClone and Bristol-Myers Squibb. Earlier in his career, he served in various financial positions at Bristol-Myers Squibb over a 15-year tenure. He served on the board of directors and the audit committee of U.S. Oncology, Inc. for five years until December 2010, when it was acquired by McKesson. Mr. Lynch received his B.A. in mathematics from Wesleyan University and his M.B.A. from the Darden Graduate School of Business Administration at the University of Virginia.

John Agwunobi is chief executive officer and chairman of the board of Herbalife Nutrition, a premier global nutrition company that serves customers in 94 countries. Agwunobi is a passionate proponent of Herbalife Nutrition’s mission to improve the nutrition habits of people worldwide, strengthening our communities and providing independent distributors a business opportunity to earn supplemental income. As chief executive officer, he sets the strategy for Herbalife Nutrition, overseeing all aspects of the company’s growth and ensuring that the company continues to be recognized worldwide as a leading nutrition company with a keen focus on initiatives that can positively impact issues affecting global society, including overweight and obesity, healthy aging, and a business opportunity.

Agwunobi previously served as co-president and chief health and nutrition officer, directing the company’s nutrition philosophy. Since joining the company in 2016, Agwunobi has worked closely with Herbalife Nutrition independent distributors and customers, ensuring that the company continuously innovates in the areas of product development, technology, marketing and distributor sales. He also led the Herbalife Nutrition Institute, the Herbalife Nutrition Advisory Board, and the Herbalife Dietetic Advisory Board and worked with the company’s Ph.D.s and scientists to integrate nutrition science into Herbalife Nutrition products.

Agwunobi brings a wealth of experience from both the public and private sectors to his role. Most notably, in the private sector, he served as senior vice president and president of health and wellness for the world’s largest retailer, Walmart, where he led a team of over 65,000 and grew the business from $25 billion to over $30 billion. In the public sector, Agwunobi served as Florida’s secretary of health and later as an admiral in the U.S. Public Health Services Commissioned Corps and the assistant secretary of health for the U.S. Department of Health and Human Services. In these roles, he was responsible for disease prevention and health promotion. He oversaw the Centers for Disease Control, the National Institutes of Health, the Food and Drug Administration, the office of the U.S. Surgeon General, and numerous other public health offices and programs.

Agwunobi has a broad educational background that includes a master's degree in public health from Johns Hopkins University and a master's degree in business administration from Georgetown University. He completed his pediatric residency at Howard University and is currently a licensed physician in Florida and Maryland. He serves on numerous boards, including the U.S. African Development Foundation and bluebird bio.

Wendy L. Dixon, Ph.D., has served as a member of our board of directors since April 2013. In 2012, Dr. Dixon served as senior advisor at The Monitor Group. Dr. Dixon serves as a member of the board of directors for a number of biopharmaceutical companies, including Alkermes PLC, Incyte Corporation, Eleven Biotherapeutics, Inc. and Voyager Therapeutics, Inc., and formerly for Orexigen Therapeutics Inc., Furiex Pharmaceuticals, Inc., which was sold to Forest Laboratories, LLC as a subsidiary of Allergan in 2014, Ardea Biosciences, Inc., which was sold to AstraZeneca PLC in 2012, and Dentsply International Inc., as well as a private company, Edimer Pharmaceuticals, Inc. Dr. Dixon also served as chief marketing officer and president of Global Marketing for Bristol-Myers Squibb and as a member of the CEO’s Executive Committee from 2001 to 2009. She has had an over 30-year career in the pharmaceutical and biotechnology business, combining a technical background and experience in drug development and regulatory affairs with commercial responsibilities in building and leading organizations and launching and growing more than 20 pharmaceutical products including Tagamet, Fosamax, Singulair, Plavix, Abilify, Reyataz and Baraclude. From 1996 to 2001, she was senior vice president, marketing at Merck and prior to that she held executive management positions at West Pharmaceuticals, Osteotech and Centocor, and various positions at SmithKline and French (now GlaxoSmithKline) in marketing, regulatory affairs, project management and as a biochemist. Dr. Dixon received her B.Sc., M.Sc. and Ph.D. from the University of Cambridge (UK).

Ramy Ibrahim, MD, is a recognized leader of clinical development in immunotherapy. He helped develop some of the first breakthrough treatments in the field during his tenure at Bristol-Myers Squibb and MedImmune/AstraZeneca. He was part of the team that led to the approval of the first check point inhibitor for the treatment of cancer (Anti-CTLA4). During that time, he worked very closely with regulators including US FDA, EMEA, PMDA and contributed to the efforts to refine guidelines for cancer immunotherapy development. Given the novelty of the mechanism of action of cancer immunotherapies, and the unique kinetics of responses observed in some patients treated with those agents, Ramy was part of the task force that was established to revise the standard response criteria used to assess the efficacy of check point inhibitors. He also worked on establishing treatment guidelines for the management of the immune related adverse events (irAEs) observed in patients treated with them.

Dr. Ibrahim currently serves as Chief Medical Officer at bit.bio. Previously, Dr. Ibrahim was CMO at the Parker Institute for Cancer Immunotherapy. As part of his role, he built clinical trial management and the translational capabilities within the Institute that enabled the conduct of multi-center clinical trials across the Parker centers. In addition, he played a critical role in establishing Newco built around IP and discoveries generated from the member researchers. The support provided by PICI included seed funds, business plans and clinical development plans.

At AstraZeneca, Dr. Ibrahim was the vice president and Therapeutic area head for Immuno-Oncology clinical development, leading the global clinical team developing multiple immunotherapies. He led the team that designed and executed registrational studies that led to the approval of some of those agents such as Durvalumab in locally advanced NSCLC which transformed standard of care of those patients.

As a member of the Bristol-Myers Squibb Immuno-oncology program, he served on the Yervoy (ipilimumab) clinical team supporting the program from early phase II through multiple global launches of the first FDA-approved immune checkpoint inhibitor. In addition, he played a key role in early development for nivolumab (PD-1), PD-L1 and CD137 antibody.

Throughout his career, Dr. Ibrahim has been involved with global cancer immunotherapy societies such as ASCO, AACR, Society of Immunotherapy for Cancer (SITC), Friends of Cancer research, the Cancer Research Institute and Cancer Support Community (CSC). He is a trained medical oncologist, who conducted bench and clinical immunotherapy research at the cancer vaccine branch of the National Cancer Institute in Bethesda, MD.

Nick Leschly has served as our chief bluebird since September 2010. Formerly, Nick was a partner and founding member of Third Rock Ventures in 2007. Nick played an integral role in the overall formation, development and business strategy of several of Third Rock’s portfolio companies, including Agios Pharmaceuticals, Inc. and Edimer Pharmaceuticals, Inc. Prior to joining Third Rock, he worked at Millennium Pharmaceuticals, leading several early-stage drug development programs and served as the product leader for VELCADE. Nick also founded and served as chief executive officer of MedXtend Corporation. He received his B.S. in molecular biology from Princeton University and his MBA from Wharton Business School. He currently serves as a board member of the Biotechnology Innovation Organization (BIO) and Synlogic Therapeutics.

William R. Sellers, M.D. has served as a member of our board since September 2019. Dr. Sellers currently leads a research group focused on translating genomic discoveries into new therapeutics as a Core Institute Member at the Broad Institute of MIT and Harvard, and as a Professor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School. Previously, Dr. Sellers directed cancer drug discovery and early cancer clinical development at the Novartis Institutes for Biomedical Research overseeing scientists, clinicians and clinical staff on sites in Cambridge, East Hanover, Basel and Shanghai from 2005-2016. During his tenure he conceptualized and directed a collaboration with the Broad Institute on the Cancer Cell Line Encyclopedia, the development of the Novartis Primary Derived Xenograft Encyclopedia and large-scale efforts to functionally characterize the cancer genome. Along with Dr. Carl June, he co-chaired the CART research collaboration with the University of Pennsylvania that brought CTL019 to a recent FDA approval.

Dr. Sellers was previously an Associate Professor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School and an Associate Member of the Broad Institute. Together with Matthew Meyerson, he initiated and developed large-scale efforts to re-sequence genes in diverse cancer types, which led to the development of the widely used GISTIC algorithm, the discovery of EGFR mutations in lung adenocarcinoma and the discovery of the oncogenic role of the MITF gene in melanoma. In addition, his work advanced the understanding of the molecular mechanisms of growth regulation of the PTEN tumor suppressor gene.

Dr. Sellers received his B.S. from Georgetown University in 1982 and M.D. from the University of Massachusetts Medical School in 1986. He completed residency training in Internal Medicine at the University of California San Francisco in 1989 and trained in Medical Oncology at the Dana-Farber Cancer Institute. Dr. Sellers is a former member of the National Cancer Advisory Board.

Mark Vachon has served as a member of our board of directors since July 2014. Mr. Vachon served as an executive vice president sales, integration and operations at Change Healthcare Holdings, Inc. from November 2016 to April 2018. For over 30 years, Mr. Vachon held a variety of leadership positions across the General Electric organization, and was a company officer beginning in 1999 and a member of GE’s Corporate Executive Council. Mr. Vachon was president and chief executive officer of GE Healthcare Americas from 2009 and 2010, and prior to that he was president and chief executive officer of Global Diagnostics Imaging, GE Healthcare, between 2006 and 2009. Between 2003 and 2006, Mr. Vachon was executive vice president and chief financial officer of GE Healthcare. Mr. Vachon serves on the board of trustees of Northeastern University and the board of directors of Numotion, and the Charitable Health and Retirement Trust. Mr. Vachon holds a B.S. in Finance from Northeastern University and an M.A. from Boston College.

Denice Torres has served as a member of our board of directors since August 2020. She has 25 years of management experience in pharmaceuticals, medical devices, and consumer healthcare.

From 2005-2017, Denice served in senior leadership roles at Johnson & Johnson, including Chief Strategy and Transformation Officer for the global medical device business. Denice is credited for leading one of the most significant transformations in J&J history. Following a series of recalls and the initiation of a consent decree, Denice assumed the role of President, McNeil Consumer Healthcare. From 2011-2015, she led the recovery of OTC brands, including the iconic Tylenol portfolio, by transforming the business operations, manufacturing and quality systems, commercialization approach, and creating high levels of employee engagement across all functions of the business. As a result, Healthcare Businesswoman Association (HBA) named Denice Woman of the Year in 2015. At J&J, Denice also served as President of Janssen Pharmaceuticals (CNS) where she drove turnaround growth by evolving operations, commercialization, patient focus, and building a high performing culture.

Before joining J&J, Denice had a highly successful, 14-year career at Lilly where she was the executive director of global neuroscience and director of U.S. women’s health. She is founder of The Mentoring Place, a volunteer platform that focuses on helping accelerate the careers of women.

Denice received a Bachelor of Science in Psychology from Ball State University, Doctor of Jurisprudence from Indiana University, and Master’s in Business Administration from the University of Michigan. She is a member of the Michigan Bar Association.